National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost-effectiveness of Oncotype DX® to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positive, early-stage breast cancer in Ireland.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
24/05/2011 22/07/2011 Reimbursement not recommended at the submitted price

3rd October 2011

Following a price revision the NCPE now consider Oncotype DX a cost-effective therapy to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positve, early stage breast cancer in Ireland.

Oncotype DX summary

 

July 2013

The HSE has approved reimbursement following confidential price negotiations.